Avantor Q3 2026 Earnings: Organic Growth Returned, but Adjusted Margins Narrowed

Avantor (NYSE: AVTR) reported fiscal Q3 2026 net sales of $1.698 billion, up 4.6% year over year, while diluted GAAP EPS improved to $0.30 from a loss of $1.04. Organic sales increased 5.2%, but adjusted EPS remained flat at $0.22 and adjusted profitability declined as unfavorable product mix and higher SG&A expenses weighed on the VWR segment.

Core Financial Results

Revenue returned to year-over-year growth, with a 0.6% currency headwind reducing reported growth below the 5.2% organic rate. Gross profit increased more slowly than sales, while adjusted operating income and adjusted EBITDA declined despite the higher revenue.

GAAP comparisons were heavily affected by unusual items. The prior-year quarter included a $785.0 million non-cash goodwill impairment, while Q3 2026 included a $105.4 million income tax benefit. Adjusted net income, which removes these and other specified items, declined to $146.4 million from $151.1 million.

Business and Segment Performance

Both operating segments generated quarterly organic growth. VWR Distribution & Services remained the larger growth contributor, while Bioscience & Medtech Products returned to organic growth and maintained its segment margin.

VWR’s higher sales volume did not offset unfavorable product mix and increased SG&A expenses, resulting in lower adjusted operating income and a 1.5-point margin contraction. Bioscience & Medtech benefited from higher volume and commercial execution, but those benefits were offset by higher SG&A expenses, leaving its margin unchanged.

Revenue Growth Outpaced Profit as VWR Mix Pressured Margins

The central issue in the quarter was the divergence between sales growth and adjusted profitability. Organic revenue increased 5.2%, but adjusted operating income fell by about 4.1%, and its margin narrowed from 14.6% to 13.4%.

This divergence was concentrated in VWR, which produced the faster organic growth but operates at a substantially lower margin than Bioscience & Medtech. VWR’s unfavorable product mix and higher SG&A expenses reduced the incremental profit generated from increased volume. Bioscience & Medtech’s return to growth helped, but its stable margin was insufficient to offset VWR’s decline and slightly higher corporate expenses.

Profitability, Cash Flow, and Balance Sheet

Operating cash flow was $195.1 million, down from $207.4 million. After $38.9 million of capital expenditures, free cash flow was $156.2 million, compared with $171.7 million a year earlier. Inventory used $44.1 million of cash during the quarter, versus $33.4 million in Q3 2025, while capital spending also increased from $35.7 million.

Avantor ended September with $464.3 million of cash and cash equivalents and $3.700 billion of gross debt, producing net debt of $3.235 billion. Adjusted net leverage was 3.1 times, while GAAP net leverage was 9.6 times; the difference reflects the use of trailing adjusted EBITDA in the adjusted calculation rather than trailing GAAP net income. Cash increased from $365.4 million at the end of 2025, and the company repaid $280.6 million of debt during the first nine months of 2026.

Fiscal 2026 Guidance

Avantor raised its full-year organic revenue growth outlook and increased the lower ends of its adjusted EPS and free cash flow ranges. The adjusted EBITDA margin range was unchanged, indicating that the improved revenue outlook has not yet translated into a higher full-year margin expectation.

The company expects reported revenue growth of 1.5% to 2.0%, including a 0.75% foreign-exchange tailwind. Other assumptions include a 1.15 blended EUR/USD rate, modestly lower net interest expense, a 22.0% to 22.5% adjusted effective tax rate, and 679 million diluted shares. Free cash flow guidance excludes cash restructuring costs.

Management’s View

CEO Emmanuel Ligner attributed the return to year-over-year growth to improved execution and a sharper strategic focus under Avantor’s Revival initiative. Management highlighted the acceleration in VWR organic growth and the return of Bioscience & Medtech to organic growth, while citing stronger end markets and continued execution as the basis for sustaining the recovery.

Risks Investors Should Watch

• Margin pressure despite higher sales: VWR’s unfavorable product mix and higher SG&A expenses caused segment margin to fall to 9.7% from 11.2%. Continued growth without improved mix or expense control could limit profit expansion.
• The recovery must extend beyond one quarter: Total organic growth was only 0.3% for the first nine months of 2026 despite the 5.2% increase in Q3. Bioscience & Medtech’s nine-month organic sales were still down 1.4%, making continued improvement important to the raised full-year outlook.
• Cash flow declined year over year: Quarterly operating and free cash flow both decreased, while inventory consumed more cash and capital expenditures increased.
• Leverage remains material: Avantor carried $3.700 billion of gross debt and adjusted net leverage of 3.1 times at quarter-end, leaving debt reduction dependent on continued cash generation.
• Reported growth includes currency assumptions: Full-year reported growth guidance incorporates a 0.75% foreign-exchange tailwind, while currency reduced Q3 reported growth by 0.6%.

Summary

Avantor returned to quarterly organic growth across both segments and raised several full-year guidance ranges, showing progress in its revenue recovery. However, adjusted operating income, adjusted EBITDA, and free cash flow declined as VWR’s product mix and higher SG&A expenses pressured profitability. The next key test is whether the company can sustain the recent sales momentum while stabilizing margins, improving cash conversion, and continuing to reduce leverage.